WO2001049246A3 - Sustained release tablet formulations comprising clarithromycin - Google Patents

Sustained release tablet formulations comprising clarithromycin Download PDF

Info

Publication number
WO2001049246A3
WO2001049246A3 PCT/TR2001/000002 TR0100002W WO0149246A3 WO 2001049246 A3 WO2001049246 A3 WO 2001049246A3 TR 0100002 W TR0100002 W TR 0100002W WO 0149246 A3 WO0149246 A3 WO 0149246A3
Authority
WO
WIPO (PCT)
Prior art keywords
clarithromycin
sustained release
release
release tablet
tablet formulations
Prior art date
Application number
PCT/TR2001/000002
Other languages
French (fr)
Other versions
WO2001049246A2 (en
Inventor
Levent Oener
Ahmet Toksoez
Original Assignee
Sanovel Lac Sanay Ve T Caret A
Levent Oener
Ahmet Toksoez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to TR2000/00054A priority Critical patent/TR200000054A2/en
Priority to TR2000/00054 priority
Application filed by Sanovel Lac Sanay Ve T Caret A, Levent Oener, Ahmet Toksoez filed Critical Sanovel Lac Sanay Ve T Caret A
Publication of WO2001049246A2 publication Critical patent/WO2001049246A2/en
Publication of WO2001049246A3 publication Critical patent/WO2001049246A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

This invention covers the sustained release tablets containing hydroxypropylmethylcellulose as matrix material and clarithromycin as active ingredient. Clarithromycin is released from sustained release tablet with a rate expressed by the equation Mt/M =ktn. In this equation n is the exponent of the release kinetics and n value determines the type of release mechanism. When n value is between 0.89 to 1, release rate complies with zero-order kinetic and it is independent from time.
PCT/TR2001/000002 2000-01-05 2001-01-04 Sustained release tablet formulations comprising clarithromycin WO2001049246A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TR2000/00054A TR200000054A2 (en) 2000-01-05 2000-01-05 The sustained release tablet formulations comprising clarithromycin.
TR2000/00054 2000-01-05

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU36329/01A AU3632901A (en) 2000-01-05 2001-01-04 Sustained release tablet formulations comprising clarithromycin

Publications (2)

Publication Number Publication Date
WO2001049246A2 WO2001049246A2 (en) 2001-07-12
WO2001049246A3 true WO2001049246A3 (en) 2002-08-15

Family

ID=21622322

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2001/000002 WO2001049246A2 (en) 2000-01-05 2001-01-04 Sustained release tablet formulations comprising clarithromycin

Country Status (3)

Country Link
AU (1) AU3632901A (en)
TR (1) TR200000054A2 (en)
WO (1) WO2001049246A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1285659B1 (en) * 2001-08-13 2007-06-27 Fondazione Salvatore Maugeri - Clinica del Lavoro e della Riabilitazione Use of clarithromycin compositions in the manufacture of a medicament for the treatment of arthritis deformans
EP1720524A2 (en) * 2004-02-26 2006-11-15 Ranbaxy Laboratories Limited Extended release tablets of clarithromycin
US6642276B2 (en) * 2001-10-01 2003-11-04 M/S Ind-Swift Limited Controlled release macrolide pharmaceutical formulations
EP2283824B1 (en) 2009-07-30 2017-04-19 Special Products Line S.p.A. Compositions and formulations based on swellable matrices for sustained release of poorly soluble drugs such as clarithromycin

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0967256A (en) * 1995-08-31 1997-03-11 Taisho Pharmaceut Co Ltd Drug for common cold
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
WO2000048607A1 (en) * 1999-02-19 2000-08-24 LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. Directly compressible matrix for controlled release of single daily doses of clarithromycin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0967256A (en) * 1995-08-31 1997-03-11 Taisho Pharmaceut Co Ltd Drug for common cold
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
WO2000048607A1 (en) * 1999-02-19 2000-08-24 LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. Directly compressible matrix for controlled release of single daily doses of clarithromycin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 9720, Derwent World Patents Index; AN 1997-221692, XP002176786, "Remedies for colds- comprise ibuprofen and/or acetaminophen and clarithromycin" *

Also Published As

Publication number Publication date
WO2001049246A2 (en) 2001-07-12
TR200000054A2 (en) 2001-08-21
AU3632901A (en) 2001-07-16

Similar Documents

Publication Publication Date Title
USD506195S1 (en) Tablet personal computer
TWI324598B (en) Isoxazoline derivative and herbicide containing the same as the active ingredient
AP2397A (en) Matrix for sustained, invariant and independent release of active compounds.
PL200409B1 (en) Instantaneously spreading dised pharmacological preparation and method of forming granules
CZ295324B6 (en) Fast-dispersing dosage forms containing fish gelatin
HU0002469A3 (en) Solid thermoformable controlled-release pharmaceutical composition
IL218698D0 (en) Compounds that inhibit serine protease activity and pharmaceutical compositions containing the same
KR950013501A (en) Insoluble i.e. oral sustained release tablet comprising an immediate release tablet core of the drug with a sustained release coating material
MXPA03000007A (en) Confectionery product containing active ingredients.
MXPA04004791A (en) Micronized film-forming powder comprising an active substance.
EP2277510A3 (en) Controlled release preparation
MY125919A (en) Bioadhesive progressive hydration tablets and methods of making and using the same
RU94032150A (en) Medicinal agent exhibiting delayed release of active-acting substance
EP2266542A3 (en) Controlled release nanoparticulate compositions
WO2003088756A3 (en) Triple coated confectionery tablet product
WO2004012699A3 (en) Modified release composition comprising coated micro matrix particles containing the high soluble active ingredient and a release controlling agent
PL372084A1 (en) 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
ZA200502138B (en) Child-resistant pill dispenser.
IL139996A (en) Compounds which elevate pyruvate dehydrogenase (pdh) activity, processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of medicaments for use in the elevation of pdh activity in warm-blooded animals
HU0400566A3 (en) Pharmaceutical preparation comprising an active dispersed on a matrix
GEP20053420B (en) Sustained Release Ranolanolazine Formulation
ZA200403928B (en) Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient
AU4725893A (en) Sustained release tablets containing bupropion
BR9914251A (en) Formulations for oral sustained release
AU2002328627A1 (en) Tetrazoyl oxime derivative and agricultural chemical containing the same as active ingredient

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP